A study to assess the role of Tranexamic acid in reducing blood loss in Cesarean Sections in women at high risk for Postpartum Hemorrhage
- Conditions
- Health Condition 1: O721- Other immediate postpartum hemorrhage
- Registration Number
- CTRI/2021/03/031690
- Lead Sponsor
- Jawaharlal Nehru Medical College KLE University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Pregnant women at gestational age of 34 weeks or more, who are to undergo elective or emergency caesarean delivery, with at least one risk factor including Obesity, Chronic Hypertension, Gestational hypertension, Pre-eclampsia, Eclampsia, Anemia, Use of Oxytocin augmentation >4hrs, Multiparity (Parity >4), Multiple pregnancy, Abnormally implanted placenta, Placenta previa, Abruption, Uterine Leiomyomas, Polyhydramnios, Fetal macrosomia, Previous LSCS, History of postpartum hemorrhage in previous pregnancy, Chorioamnionitis and Cholestasis of pregnancy
Patients with Impaired colour vision, Known cardiovascular, renal or liver disorders, Current or past history of DVT, Anticoagulant therapy, Coagulation defects, HELLP syndrome and Sensitivity to Tranexamic acid.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in estimated blood loss in cesarean sections by formula using difference between pre and post op hematocrit and estimated blood volume. <br/ ><br> <br/ ><br>Difference in pre and post op hemoglobinTimepoint: 1 year
- Secondary Outcome Measures
Name Time Method eed for blood and blood product transfusion intra-op or post-operatively <br/ ><br> <br/ ><br>Need for additional uterotonics/surgical procedure during cesarean section <br/ ><br> <br/ ><br>Need for additional Tranexamic acid to control bleeding <br/ ><br> <br/ ><br>Maternal and fetal complications related to Tranexamic acidTimepoint: 1 year